SAFETY AND EFFICACY OF THE ANTI-TISSUE FACTOR PATHWAY INHIBITOR MARSTACIMAB IN PARTICIPANTS WITH SEVERE HEMOPHILIA WITHOUT INHIBITORS: RESULTS FROM THE PHASE 3 BASIS TRIAL AND ONGOING LONG-TERM EXTENSION STUDY

被引：0
|
作者：
Acharya, Suchitra S. [1 ]
Matino, Davide [2 ]
Palladino, Andrew [3 ]
Hwang, Eunhee [3 ]
McDonald, Regina [4 ]
Taylor, Carrie Turich [5 ]
Teeter, John [5 ]
机构：
[1] Northwell Hlth, Northwell Hemostasis & Thrombosis Ctr, Cohen Childrens Med Ctr, New Hyde Pk, NY USA
[2] McMaster Univ, 237 Barton St East, Hamilton, ON, Canada
[3] Pfizer Inc, Collegeville, PA USA
[4] Pfizer Inc, New York, NY USA
[5] Pfizer Inc, Groton, CT USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4 / 4
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of the Anti-Tissue Factor Pathway Inhibitor Marstacimab in Participants with Severe Hemophilia without Inhibitors: Results from the Phase 3 Basis Trial
    Matino, Davide
    Acharya, Suchitra
    Palladino, Andrew
    Hwang, Eunhee
    McDonald, Regina
    Taylor, Carrie Turich
    Teeter, John
    BLOOD, 2023, 142
  • [2] Dose escalation of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia without inhibitors: Results from the phase 3 basis and long-term extension trials
    Jimenez-Yuste, Victor
    Palladino, Andrew
    McDonald, Regina
    McComb, Bryan
    Hwang, Eunhee
    Taylor, Carrie Turich
    Teeter, John
    HAEMOPHILIA, 2024, 30 : 92 - 93
  • [3] Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results
    Mahlangu, Johnny
    Lamas, Jose Luis
    Morales, Juan Cristobal
    Malan, Daniel R.
    Teeter, John
    Charnigo, Robert J.
    Hwang, Eunhee
    Arkin, Steven
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (02) : 240 - 248
  • [4] Marstacimab, an Anti-Tissue Factor Pathway Inhibitor, in Participants with Hemophilia. or B, with and without Inhibitors: An Integrated Analysis of Safety
    Acharya, Suchitra
    Matino, Davide
    Mahlangu, Johnny
    Turich, Carrie
    Hwang, Eunhee
    Hinnershitz, Tina
    Mefyod, Eugeny
    Palladino, Andrew
    Biondo, Francesca
    Gould, Travis
    Teeter, John
    BLOOD, 2023, 142
  • [5] Immunogenicity and safety of marstacimab, an anti-tissue factor pathway inhibitor, in participants with haemophilia A or B and without inhibitors
    Acharya, S. S.
    Taylor, C. T.
    Hwang, E.
    Hinnershitz, T.
    Raje, S. V.
    Mefyod, E.
    Palladino, A.
    Biondo, F.
    Teeter, J.
    HAEMOPHILIA, 2024, 30 : 127 - 127
  • [6] Long-Term Durability, Safety and Efficacy of Fitusiran Prophylaxis in People with Hemophilia a or B, with or without Inhibitors - Results from the Phase II Study
    Pipe, Steven W.
    Pasi, John
    Lissitchkov, Toshko
    Ragni, Margaret V.
    Negrier, Claude
    Yu, Qifeng
    Poloskey, Stacey
    Mei, Baisong
    Andersson, Shauna R.
    BLOOD, 2020, 136
  • [7] Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors
    Shima, Midori
    Hanabusa, Hideji
    Taki, Masashi
    Matsushita, Tadashi
    Sato, Tetsuji
    Fukutake, Katsuyuki
    Kasai, Ryu
    Yoneyama, Koichiro
    Yoshida, Hiroki
    Nogami, Keiji
    BLOOD ADVANCES, 2017, 1 (22) : 1891 - 1899
  • [8] Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
    Busse, William W.
    Bleecker, Eugene R.
    FitzGerald, J. Mark
    Ferguson, Gary T.
    Barker, Peter
    Sproule, Stephanie
    Olsson, Richard F.
    Martin, Ubaldo J.
    Goldman, Mitchell
    LANCET RESPIRATORY MEDICINE, 2019, 7 (01): : 46 - 59
  • [9] Long-Term Efficacy and Safety of Lomitapide for the Treatment of Homozygous Familial Hypercholesterolemia: Results of the Phase 3 Extension Trial
    Blom, Dirk
    Averna, Maurizio
    Meagher, Emma
    Theron, Hendrik du Toit
    Sirtori, Cesare
    Hegele, Robert
    Shah, Prediman
    Gaudet, Daniel
    Stefanutti, Claudia
    Vigna, Giovanni
    Foulds, Pam
    Bloedon, LeAnne
    Rader, Daniel
    Cuchel, Marina
    CIRCULATION, 2015, 132
  • [10] Updated results of an ongoing long-term phase 1/2 study of emicizumab (ACE910) in hemophilia A patients with or without inhibitors
    Hanabusa, Hideji
    Taki, Masashi
    Matsushita, Tadashi
    Sato, Tetsuji
    Fukutake, Katsuyuki
    Kasai, Ryu
    Yoneyama, Koichiro
    Yoshida, Hiroki
    Shima, Midori
    HAEMOPHILIA, 2016, 22 : 76 - 76
12345